Who
William McKee
Director
Company insider
Files Form 4 as: Director, Assertio Holdings; Director, Rein Therapeutics; Chief Financial Officer, C4 Therapeutics; Director, Agile Therapeutics; Director, Assertio Therapeutics; Director, Dare Bioscience; Director, Auxilium Pharmaceuticals; EVP, CFO, Barr Pharmaceuticals.
In numbers
- Trades disclosed
- 103
- Buys
- 1
- Sells
- 8
- Bought
- $100K
- Sold
- $5.6M
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 3 Jan 2006
- Last trade
- 16 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 16 Jun 2026 | Assertio HoldingsBiotechnology | SEC FORM 4 Code U | —27,936 at $0.00 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdingsoption or derivative | SEC FORM 4 Code D | —5,415 | filing |
| 16 Jun 2026filed 16 Jun 2026 | Assertio Holdings | SEC FORM 4 Code U | —27,936 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | Assertio HoldingsBiotechnology | SEC FORM 4 Code A | —4,851 at $0.00 | filing |
| 5 May 2026filed 6 May 2026 | Assertio Holdings | SEC FORM 4 Code A | —4,851 at $0.00 | filing |
| 7 May 2025filed 9 May 2025 | Assertio Holdingsoption or derivative | SEC FORM 4 Code A | —81,225 at $0.00 | filing |
| 7 May 2025filed 9 May 2025 | Assertio Holdings | SEC FORM 4 Code A | —53,750 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | Assertio Holdingsoption or derivative | SEC FORM 4 Code A | —81,225 at $0.00 | filing |
| 23 May 2024filed 28 May 2024 | Assertio Holdings | SEC FORM 4 Code A | —53,750 at $0.00 | filing |
| 14 Aug 2023filed 15 Aug 2023 | Assertio Holdings | SEC FORM 4 Sold | $69K22,000 at $3.14 | filing |
| 10 May 2023filed 12 May 2023 | Assertio Holdingsoption or derivative | SEC FORM 4 Code A | —3,821 at $0.00 | filing |
| 10 May 2023filed 12 May 2023 | Assertio Holdings | SEC FORM 4 Code A | —31,194 at $0.00 | filing |
| 15 Jun 2022filed 17 Jun 2022 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,500 at $0.00 | filing |
| 12 May 2022filed 16 May 2022 | Assertio Holdings | SEC FORM 4 Sold | $52K22,322 at $2.35 | filing |
| 4 May 2022filed 6 May 2022 | Assertio Holdings | SEC FORM 4 Code A | —86,286 at $0.00 | filing |
| 15 Jun 2021filed 17 Jun 2021 | RNTX Rein Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —96,000 at $0.00 | filing |
| 11 May 2021filed 13 May 2021 | Assertio Holdings | SEC FORM 4 Code A | —357,143 at $0.00 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)CCCC · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)CCCC · dailypolitical.com · 15 Oct 2026
0 headlines in the last 90 days name William McKee; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.